TOT BIOPHARM International Company Limited (1875.HK)
- Previous Close
2.200 - Open
2.230 - Bid 2.210 x --
- Ask 2.320 x --
- Day's Range
2.220 - 2.230 - 52 Week Range
0.800 - 3.400 - Volume
46,000 - Avg. Volume
32,996 - Market Cap (intraday)
1.61B - Beta (5Y Monthly) 0.22
- PE Ratio (TTM)
-- - EPS (TTM)
-0.050 - Earnings Date Aug 9, 2024 - Aug 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
3.88
TOT BIOPHARM International Company Limited, an investment holding company, engages in the research, development, manufacturing, and marketing of anti-tumor drugs in China. The company develops and markets Pusintin, a bevacizumab injection for the treatment of non-squamous non-small cell lung cancer; metastatic colorectal cancer; recurrent glioblastoma multiforme; epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer; cervical cancer; and hepatocellular carcinoma. It also offers Tazian, a temozolomide capsule for the treatment of glioblastoma multiforme or anaplastic astrocytoma; and Megaxia, a megestrol acetate oral suspension for the treatment of anorexia associated with acquired immunode¬ciency syndrome, as well as signi¬cant weight loss of AIDS and cancer patients caused by cachexia. In addition, the company is developing TAB014 that has completed Phase III clinical trial for the treatment of wet age-related macular degeneration (wAMD). Further, it develops products under preclinical trials, including TAE020 for acute myeloid leukemia; and TAC020 for the treatment various solid tumors. Additionally, the company engages in contract development and manufacturing organization (CDMO)/contract manufacture organization (CMO) business; and license-out of self-developed biological drugs. TOT BIOPHARM International Company Limited was incorporated in 2009 and is headquartered in Suzhou, China.
www.totbiopharm.comRecent News: 1875.HK
Performance Overview: 1875.HK
Trailing total returns as of 6/7/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 1875.HK
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 1875.HK
Valuation Measures
Market Cap
1.61B
Enterprise Value
1.60B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.88
Price/Book (mrq)
2.13
Enterprise Value/Revenue
1.87
Enterprise Value/EBITDA
139.67
Financial Highlights
Profitability and Income Statement
Profit Margin
-4.84%
Return on Assets (ttm)
-0.98%
Return on Equity (ttm)
-5.39%
Revenue (ttm)
780.63M
Net Income Avi to Common (ttm)
-37.76M
Diluted EPS (ttm)
-0.050
Balance Sheet and Cash Flow
Total Cash (mrq)
358.36M
Total Debt/Equity (mrq)
50.34%
Levered Free Cash Flow (ttm)
-143.74M